Shanghai Hile Bio-Technology Co., Ltd. (SHA:603718)

Market Cap	3.13B -27.9%
Revenue (ttm)	246.35M +11.7%
Net Income	171.34M +1,953.2%
EPS	0.27 +2,017.7%
Shares Out	651.90M
PE Ratio	18.09
Forward PE	n/a
Dividend	0.08 (1.63%)
Ex-Dividend Date	Jul 15, 2025

Volume	30,000,970
Average Volume	25,561,634
Open	4.880
Previous Close	4.900
Day's Range	4.780 - 4.930
52-Week Range	4.790 - 8.010
Beta	0.51
RSI	24.66
Earnings Date	Apr 30, 2026

About SHA:603718

Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent products, and related diagnostic kits, including matrix metalloprot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1981
• Employees: 366
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603718

Financial Performance

In 2024, SHA:603718's revenue was 271.04 million, an increase of 12.59% compared to the previous year's 240.72 million. Earnings were 171.18 million, an increase of 172.28%.